electroCore (ECOR) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed electroCore (ECOR) over the past year, gaining 116.3% versus a gain of 84.7%. electroCore is the larger company by market cap ($85.7 million vs $85.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ECOR | NRXS |
|---|---|---|
| Share price | $9.51 | $6.77 |
| Market cap | $85.74M | $85.02M |
| 1-day change | -2.16% | -0.88% |
| YTD return | +112.04% | +49.12% |
| 1-year return | +84.66% | +116.29% |
| 5-year return | -36.41% | — |
| EPS (TTM) | $-1.65 | $-0.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.70 | $9.33 |
| 52-week low | $4.41 | $2.21 |
| Distance from 52-week high | -25.12% | -27.44% |
| Analyst consensus | none | none |
| Avg. price target upside | +101.58% | +62.48% |
| Average volume | 80.51K | 107.27K |
| Shares outstanding | 9.02M | 12.56M |
| Employees | 83 | 24 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed ECOR by 31.6 percentage points over the past year.
About electroCore
ECOR stock →electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Healthcare · Medical Devices · 83 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Healthcare · Biotechnology · 24 employees
ECOR vs NRXS FAQ
Which is bigger, electroCore or Neuraxis?
electroCore (ECOR) is larger, with a market capitalization of $85.74M compared with $85.02M for Neuraxis (NRXS).
Which stock has performed better over the past year, ECOR or NRXS?
NRXS returned +116.29% over the past 12 months, compared with +84.66% for ECOR (price return, excluding dividends). Past performance does not predict future results.
Are electroCore and Neuraxis in the same industry?
Both are in the Healthcare sector, but in different industries: Medical Devices for electroCore and Biotechnology for Neuraxis.